Audit Review Table									
UnitedHealthcare Community Plan, Inc - New Mexico	Org ID: 12829	, SubID: 10138,	Medicaid, Spec	Area: None, Sp	ec Proj: None); Me	easurement Year - 2013			
The Auditor lock has been applied to this submission.									
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment			
Effectiveness of Care: Prevention and Screening									
Adult BMI Assessment (aba)	Υ			71.51%	R	Reportable			
Weight Assessment and Counseling for Nutrition									
and	Υ								
Physical Activity for Children/Adolescents (wcc)									
BMI Percentile				NA	R	Denominator fewer than 30			
Counseling for Nutrition				NA	R	Denominator fewer than 30			
Counseling for Physical Activity				NA	R	Denominator fewer than 30			
Childhood Immunization Status (cis)	Υ								
DTaP				NA	R	Denominator fewer than 30			
IPV				NA	R	Denominator fewer than 30			
MMR				NA	R	Denominator fewer than 30			
HiB				NA	R	Denominator fewer than 30			
Hepatitis B				NA	R	Denominator fewer than 30			
VZV				NA	R	Denominator fewer than 30			
Pneumococcal Conjugate				NA	R	Denominator fewer than 30			
Hepatitis A				NA	R	Denominator fewer than 30			
Rotavirus				NA	R	Denominator fewer than 30			
Influenza				NA	R	Denominator fewer than 30			
Combination #2				NA	R	Denominator fewer than 30			
Combination #3				NA	R	Denominator fewer than 30			
Combination #4				NA	R	Denominator fewer than 30			
Combination #5				NA	R	Denominator fewer than 30			
Combination #6				NA	R	Denominator fewer than 30			
Combination #7				NA	R	Denominator fewer than 30			
Combination #8				NA	R	Denominator fewer than 30			
Combination #9				NA	R	Denominator fewer than 30			
Combination #10				NA	R	Denominator fewer than 30			
Immunizations for Adolescents (ima)	Υ								
Meningococcal				NA	R	Denominator fewer than 30			

Tdap/Td			NA	R	Denominator fewer than 30
Combination #1			NA	R	Denominator fewer than 30
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Υ		NA	R	Denominator fewer than 30
Lead Screening in Children (Isc)	Υ		NA	R	Denominator fewer than 30
Breast Cancer Screening (bcs)	Υ		44.40%	R	Reportable
Cervical Cancer Screening (ccs)	Υ		43.06%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Υ		NA	R	Denominator fewer than 30
Chlamydia Screening in Women (chl)	Υ				
16-20 Years			NA	R	Denominator fewer than 30
21-24 Years			NA	R	Denominator fewer than 30
Total			NA	R	Denominator fewer than 30
Effectiveness of Care: Respiratory Conditions					
Appropriate Testing for Children with Pharyngitis (cwp)	Υ	Υ	NA	R	Denominator fewer than 30
Appropriate Treatment for Children With URI (uri)	Υ	Y	NA	R	Denominator fewer than 30
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Υ	Y	22.03%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Υ		26.19%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Υ	Y			
Systemic Corticosteroid			60.00%	R	Reportable
Bronchodilator			93.75%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y			
5-11 Years			NA	R	Denominator fewer than 30
12-18 Years			NA	R	Denominator fewer than 30
19-50 Years			53.33%	R	Reportable
51-64 Years			57.58%	R	Reportable
Total			56.92%	R	Reportable

Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				NA	R	Denominator fewer than 30
5-11 Years - Medication Compliance 75%				NA	R	Denominator fewer than 30
12-18 Years - Medication Compliance 50%				NA	R	Denominator fewer than 30
12-18 Years - Medication Compliance 75%				NA	R	Denominator fewer than 30
19-50 Years - Medication Compliance 50%				NA	R	Denominator fewer than 30
19-50 Years - Medication Compliance 75%				NA	R	Denominator fewer than 30
51-64 Years - Medication Compliance 50%				NA	R	Denominator fewer than 30
51-64 Years - Medication Compliance 75%				NA	R	Denominator fewer than 30
Total - Medication Compliance 50%				64.86%	R	Reportable
Total - Medication Compliance 75%				40.54%	R	Reportable
Asthma Medication Ratio (amr)	Υ	Y				
5-11 Years				NA	R	Denominator fewer than 30
12-18 Years				NA	R	Denominator fewer than 30
19-50 Years				36.67%	R	Reportable
51-64 Years				42.42%	R	Reportable
Total				40.00%	R	Reportable
Effectiveness of Care: Cardiovascular					,	
Cholesterol Management for Patients With						
Cardiovascular Conditions (cmc)	Y					
LDL-C Screening Performed				69.75%	R	Reportable
LDL-C Control (<100 mg/dL)				36.97%	R	Reportable
Controlling High Blood Pressure (cbp)	Y		N	56.90%	R	Reportable
Persistence of Beta-Blocker Treatment After a						·
Heart	Υ	Υ		NA	R	Denominator fewer than 30
Attack (pbh)						
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Υ					
Hemoglobin A1c (HbA1c) Testing				85.88%	R	Reportable
HbA1c Poor Control (>9.0%)				49.54%	R	Reportable
HbA1c Control (<8.0%)				41.90%	R	Reportable
HbA1c Control (<7.0%)				NR	NR	Plan chose not to report
Eye Exam (Retinal) Performed				43.98%	R	Reportable

LDL-C Screening Performed			72.69%	R	Reportable
LDL-C Control (<100 mg/dL)			37.04%	R	Reportable
Medical Attention for Nephropathy			82.87%	R	Reportable
Blood Pressure Control (<140/80 mm Hg)			43.75%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)			62.50%	R	Reportable
Effectiveness of Care:					
Musculoskeletal					
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y	74.42%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Υ		77.78%	R	Reportable
Effectiveness of Care: Behavioral Health					
Antidepressant Medication Management (amm)	Υ	Υ			
Effective Acute Phase Treatment			50.99%	R	Reportable
Effective Continuation Phase Treatment			37.09%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Υ	Y			
Initiation Phase			NA	R	Denominator fewer than 30
Continuation and Maintenance (C&M) Phase			NA	R	Denominator fewer than 30
Follow-Up After Hospitalization for Mental Illness (fuh)	Υ	N			
30-Day Follow-Up			NB	R	Required benefit not offered
7-Day Follow-Up			NB	R	Required benefit not offered
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y	80.70%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Υ		55.81%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Υ		NA	R	Denominator fewer than 30

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y	50.00%	R	Reportable
Effectiveness of Care: Medication Management					
Annual Monitoring for Patients on Persistent Medications (mpm)	Υ	Y			
ACE Inhibitors or ARBs			88.60%	R	Reportable
Digoxin			NA NA	R	Denominator fewer than 30
Diuretics			91.52%	R	Reportable
Anticonvulsants			67.78%	R	Reportable
Total			86.03%	R	Reportable
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (aap)	Υ				
20-44 Years			96.18%	R	Reportable
45-64 Years			99.07%	R	Reportable
65+ Years			97.18%	R	Reportable
Total			98.16%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Υ				
12-24 Months			NA	R	Denominator fewer than 30
25 Months - 6 Years			NA	R	Denominator fewer than 30
7-11 Years			NA	R	Denominator fewer than 30
12-19 Years			NA	R	Denominator fewer than 30
Annual Dental Visit (adv)	Υ	Υ			
2-3 Years			NA	R	Denominator fewer than 30
4-6 Years			NA	R	Denominator fewer than 30
7-10 Years			NA	R	Denominator fewer than 30
11-14 Years			NA	R	Denominator fewer than 30
15-18 Years			NA	R	Denominator fewer than 30
19-21 Years			NA	R	Denominator fewer than 30
Total			51.52%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Υ	N			

Initiation of AOD Treatment: 13-17 Years			NB	R	Required benefit not offered
Engagement of AOD Treatment: 13-17 Years			NB	R	Required benefit not offered
Initiation of AOD Treatment: 18+ Years			NB	R	Required benefit not offered
Engagement of AOD Treatment: 18+ Years			NB	R	Required benefit not offered
Initiation of AOD Treatment: Total			NB	R	Required benefit not offered
Engagement of AOD Treatment: Total			NB	R	Required benefit not offered
Prenatal and Postpartum Care (ppc)	Y	N			
Timeliness of Prenatal Care			NA	R	Denominator fewer than 30
Postpartum Care			NA	R	Denominator fewer than 30
Call Answer Timeliness (cat)	Υ		93.40%	R	Reportable
Utilization					
Frequency of Ongoing Prenatal Care (fpc)	Υ	N			
<21 Percent			NA	R	Denominator fewer than 30
21-40 Percent			NA	R	Denominator fewer than 30
41-60 Percent			NA	R	Denominator fewer than 30
61-80 Percent			NA	R	Denominator fewer than 30
81+ Percent			NA	R	Denominator fewer than 30
Well-Child Visits in the First 15 Months of Life (w15)	Y				
0 Visits			NA	R	Denominator fewer than 30
1 Visit			NA	R	Denominator fewer than 30
2 Visits			NA	R	Denominator fewer than 30
3 Visits			NA	R	Denominator fewer than 30
4 Visits			NA	R	Denominator fewer than 30
5 Visits			NA	R	Denominator fewer than 30
6+ Visits			NA	R	Denominator fewer than 30
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Υ		NA	R	Denominator fewer than 30
Adolescent Well-Care Visits (awc)	Υ		NA	R	Denominator fewer than 30
Frequency of Selected Procedures (fsp)	Υ			R	Reportable
Ambulatory Care: Total (amba)	Υ			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N			NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N			NR	Measure Unselected
Ambulatory Care: Other (ambd)	N			NR	Measure Unselected
, , ,					

Inpatient UtilizationGeneral Hospital/Acute Care: Total (ipua)	Y		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Dual Eligibles (ipub)	N		NR	Measure Unselected
Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc)	N		NR	Measure Unselected
Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud)	N		NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	N	R	Required benefit not offered
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N	NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N	NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N	NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Υ	N	R	Required benefit not offered
Mental Health Utilization: Dual Eligibles (mptb)	N	N	NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N	NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N	NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Υ	Υ	R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N	NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N	NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N	NR	Measure Unselected
Relative Resource Use				
Relative Resource Use for People With Diabetes (rdi)	N		NR	Measure Unselected
Relative Resource Use for People With Asthma (ras)	N	N	NR	Measure Unselected
Relative Resource Use for People With Cardiovascular Conditions (rca)	N		NR	Measure Unselected
Relative Resource Use for People With Hypertension (rhy)	N		NR	Measure Unselected

Relative Resource Use for People With COPD (rco)	N		NR	Measure Unselected
Health Plan Descriptive Information				
Board Certification (bcr)	Υ		R	Reportable
Total Membership (tlm)	Υ		R	Reportable
Enrollment by Product Line: Total (enpa)	Υ		R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N		NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N		NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N		NR	Measure Unselected
Enrollment by State (ebs)	Υ		R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	N		NR	Measure Unselected
Language Diversity of Membership (Idm)	N		NR	Measure Unselected
Weeks of Pregnancy at Time of Enrollment (wop)	Υ	N	R	Reportable